癌症相关内脏静脉血栓形成的自然病史
该回顾性队列研究在德克萨斯州休斯顿2家癌症中心纳入2011至2020年15342例新发癌症患者中的298例孤立性内脏静脉血栓形成(SpVT)患者,按癌症类型和血栓成分描述自然病史并评估抗凝实践。肝细胞癌(HCC)合并SpVT者疾病患病率最高(20%),抗凝治疗率最低(2%),6个月常规部位静脉血栓栓塞(VTE)发生率与无SpVT者相似(4.2% vs 5.2%)。非HCC癌栓患者中抗凝与更多再通相关(44% vs 15%,P = .041),但6个月常规部位VTE、大出血/临床相关非大出血或死亡率无差异。
要点
- HCC合并SpVT患者疾病患病率20%,抗凝治疗率2%,6个月常规部位VTE发生率4.2% vs 无SpVT者5.2%。
- 非HCC癌栓SpVT患者中,抗凝与更多再通相关(44% vs 15%,P = .041)。
- 癌栓 vs bland血栓与更差的总生存相关,肿瘤血栓为负性预后因素。
核心结论
- 癌症相关孤立性SpVT是一种常见但异质性的血栓性疾病,其治疗不同于常规部位VTE。
- 肿瘤血栓是负性预后因素。
- 对于bland血栓,启动抗凝需审慎考虑血栓和出血风险。
研究设计与样本
- 回顾性队列研究,纳入德克萨斯州休斯顿2家癌症中心2011至2020年15342例新发癌症诊断患者中的298例孤立性SpVT患者。
- 采用竞争风险方法估算6个月常规部位VTE及大出血/临床相关非大出血(MB/CRNMB)发生率,并在部分复查影像患者中评估静脉通畅性。
- 采用Cox回归评估与死亡率的关联。
主要发现
- 肝细胞癌(HCC)合并SpVT患者(n = 146)疾病患病率最高(20%),抗凝治疗率最低(2%),6个月常规部位VTE发生率与无SpVT者相似(4.2% vs 5.2%)。
- HCC合并SpVT患者中,癌栓 vs bland血栓与更差的总生存相关。
- 非HCC bland SpVT患者(n = 114)中,抗凝(n = 37)在非上消化道癌症和合并症较少的患者中更常见。
- 非HCC bland SpVT患者中,抗凝与更多再通相关(44% vs 15%,P = .041),但6个月常规部位VTE、MB/CRNMB或死亡率无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is uncertainty in the management of cancer-associated isolated splanchnic vein thrombosis (SpVT). OBJECTIVES: To describe the natural history of SpVT by cancer type and thrombus composition and to review anticoagulation (AC) practices and associated rates of usual-site venous thromboembolism (VTE), major and clinically relevant nonmajor bleeding (MB/CRNMB), recanalization/progression, and mortality. METHODS: We performed a retrospective cohort study in patients with SpVT at 2 cancer care centers in Houston, Texas. We estimated the incidence of usual-site VTE and MB/CRNMB at 6 months using competing risk methods and examined venous patency in a subset of patients with repeat imaging. We assessed associations with mortality using Cox regression. RESULTS: Among 15 342 patients with an incident cancer diagnosis from 2011 to 2020, we identified 298 with isolated SpVT. Patients with hepatocellular carcinoma (HCC) and SpVT (n = 146) had the highest disease prevalence (20%), lowest rate of AC treatment (2%), and similar rate of usual-site VTE (4.2%) vs those without SpVT (5.2%) at 6 months, though tumor thrombus vs bland was associated with worse overall survival. In patients with non-HCC bland SpVT (n = 114), AC (n = 37) was more common in those with non-upper gastrointestinal cancers and fewer comorbidities. AC was associated with more recanalization (44% vs 15%, P = .041) but no differences in usual-site VTE, MB/CRNMB, or mortality at 6 months. CONCLUSION: Cancer-associated isolated SpVT is a common but heterogeneous thrombotic disease that is treated differently from usual-site VTE. Tumor thrombus is a negative prognostic factor. Initiation of AC in bland thrombi requires judicious consideration of thrombotic and bleeding risk.
引用
- Shang H, Jiang JY, Guffey D, et al. Natural history of cancer-associated splanchnic vein thrombosis. J Thromb Haemost. 2024. PMID: 38309433. doi:10.1016/j.jtha.2024.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。